冠心宁片联合阿托伐他汀对老年稳定型冠心病患者临床疗效、NT-proBNP及hs-CRP水平的影响  

Effects of Guanxinning tablets combined with atorvastatin on the clinical efficacy,NT-proBNP and hs-CRP levels in elderly patients with stable coronary heart disease

作　　者：张学霞 赵宁宁 ZHANG Xue-xia;ZHAO Ning-ning(Geriatric Medicine Department,Zibo Hospital of Shandong Health Care Group,Zibo 255120,China)

机构地区：[1]山东颐养健康集团淄博医院老年医学科,255120

出　　处：《中国实用医药》2024年第13期101-104,共4页China Practical Medicine

摘　　要：目的 探讨老年稳定型冠心病(SCHD)患者采用冠心宁片联合阿托伐他汀治疗对临床疗效、氨基末端B型利钠肽前体(NT-proBNP)及超敏C反应蛋白(hs-CRP)水平的影响。方法 96例老年SCHD患者,以随机数字表法分成研究组与对照组,每组48例。对照组给予阿托伐他汀治疗,研究组给予冠心宁片联合阿托伐他汀治疗。比较两组患者临床疗效以及治疗前后的心功能[左心室收缩末期内径(LVESD)、左心室舒张末期内径(LVEDD)、左心室射血分数(LVEF)]、NT-proBNP、hs-CRP水平。结果 研究组治疗总有效率(95.83%)较对照组(81.25%)更高(P<0.05)。治疗后,两组患者LVEF均提高,LVESD、LVEDD均降低,且与对照组的(38.21±4.35)mm、(49.96±5.24)mm、(62.38±5.91)%相比,研究组LVESD(34.97±4.78)mm、LVEDD(45.71±6.32)mm更低, LVEF(67.12±4.76)%更高(P<0.05)。治疗后,两组患者NT-proBNP、hs-CRP水平均降低,且与对照组的(340.26±18.49)pg/ml、(9.31±1.75)mg/L相比,研究组的NT-proBNP(297.13±15.78)pg/ml、hs-CRP(5.84±1.10)mg/L更低(P<0.05)。结论 冠心宁片联合阿托伐他汀治疗老年SCHD患者,能够提高临床疗效,改善NT-proBNP、hs-CRP水平,促进心功能恢复。Objective To explore the effects of Guanxinning tablets combined with atorvastatin on the clinical efficacy,N-terminal pro-B-type natriuretic peptide(NT-proBNP)and hypersensitivity C-reactive protein(hs-CRP)levels in elderly patients with stable coronary heart disease(SCHD).Methods A total of 96 elderly patients with SCHD were selected,and divided into the study group and the control group by random number table method,each with 48 patients.The control group was treated with atorvastatin,and the study group was treated with Guanxinning tablets combined with atorvastatin.The clinical efficacy,cardiac function[left ventricular end-systolic diameter(LVESD),left ventricular end-diastolic diameter(LVEDD),left ventricular ejection fraction(LVEF)],NT-proBNP and hs-CRP levels before and after treatment of the two groups were compared.Results The total effective rate of the study group(95.83%)was higher than that of the control group(81.25%)(P<0.05).After treatment,LVEF was increased,LVESD and LVEDD were decreased in both groups;the study group had LVESD of(34.97±4.78)mm and LVEDD of(45.71±6.32)mm,which were lower than(38.21±4.35)and(49.96±5.24)mm in the control group;the study group had higher LVEF of(67.12±4.76)%than(62.38±5.91)%in the control group(P<0.05).After treatment,the levels of NT-proBNP and hs-CRP were decreased in both groups;the study group had NT-proBNP of(297.13±15.78)pg/ml and hs-CRP of(5.84±1.10)mg/L,which were lower than(340.26±18.49)pg/ml and(9.31±1.75)mg/L in the control group(P<0.05).Conclusion Guanxinning tablets combined with atorvastatin can improve the clinical efficacy,improve the levels of NT-proBNP and hs-CRP,and promote the recovery of cardiac function in elderly patients with SCHD.

关 键 词：老年稳定型冠心病 冠心宁片 阿托伐他汀 氨基末端B型利钠肽前体 超敏C反应蛋白 

分 类 号：R541.4[医药卫生—心血管疾病]